CN104001222A - Stent for preventing ureterostenosis and preparation method thereof - Google Patents
Stent for preventing ureterostenosis and preparation method thereof Download PDFInfo
- Publication number
- CN104001222A CN104001222A CN201410249792.6A CN201410249792A CN104001222A CN 104001222 A CN104001222 A CN 104001222A CN 201410249792 A CN201410249792 A CN 201410249792A CN 104001222 A CN104001222 A CN 104001222A
- Authority
- CN
- China
- Prior art keywords
- ureter
- solution
- stent
- preparation
- ureterostenosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a stent for preventing ureterostenosis and a preparation method of the stent. The preparation method comprises the following steps: preparing a sustained-release medicine solution, mixing paclitaxel with polylactic acid-polyglycolic acid, dissolving in a trichloromethane solution, putting the lower half part of a ureter stent into the sustained-release medicine solution, stirring with magnetic power, taking out the ureter stent, drying in a drying tank at 37 DEG C, putting the lower half part of the ureter stent into 2% trichloromethane solution of polylactic acid-polyglycolic acid, rapidly taking out, and drying in the drying tank at 37 DEG C. By adopting the stent, the defects that scar tissue hyperplasia is caused at some parts of the ureter in the tissue damage repairing and healing process after the operation, the scar tissue hyperplasia cannot be effectively inhibited after the operation, and the risk of ureterostenosis or further ureterostenosis can still happen are solved. The invention provides a ureter stent onto which a medicine can be loaded, through the sustained-release cell proliferation medicine on the surface, the hyperplasia of scar tissues is inhibited, and the effect that ureterostenosis or restenosis is not easy to happen to patients after the ureter stent is moved away is achieved.
Description
Technical field
The present invention relates to a kind of medical device, reduce the device of stricture of ureter after surgery or restenosis risk, particularly support and the preparation method of prevention stricture of ureter.
Background technology
Before the present invention, the mechanical expansion effect that the ureter bracket of implanting in operation in patients generally has by it, plays drainage of urine and the important function that prevents stricture of ureter after surgery.But in some particular procedure, due in the tissue injury reparation at some position of postoperative ureter and agglutination with scar tissue hyperplasia, if implant the ureter bracket only with mechanical expansion effect, often can not effectively suppress scar after the operation hyperproliferative, patient still has the risk of stricture of ureter or restenosis to occur after pulling out this ureter bracket.
Summary of the invention
Object of the present invention is just to overcome above-mentioned defect, the support preparation method of design and development prevention stricture of ureter.
Technical scheme of the present invention is:
The support of prevention stricture of ureter, its technical characteristics is that rack surface scribbles one deck slow releasing pharmaceutical, has repasted layer of polyethylene ketopyrrolidine K at slow releasing pharmaceutical layer
30.
The Lower Half of described support or the first half scribble two layers.
Another technical scheme of the present invention is:
The support preparation method of prevention stricture of ureter, its technical characteristics is that step comprises:
(1) preparation slow releasing pharmaceutical solution: paclitaxel is mixed with polylactic acid-polyglycolic acid, be dissolved in chloroform soln;
(2) ureter bracket Lower Half is inserted in slow releasing pharmaceutical solution to magnetic agitation;
(3) take out ureter bracket, dry at 37 DEG C of drying baker;
(4) by ureter bracket or Lower Half insert polyvinylpyrrolidone K
30in solution and fast, take out, dry at 37 DEG C of drying baker.
In described preparation slow releasing pharmaceutical solution, 1-5g paclitaxel and 10-50g polylactic acid-polyglycolic acid are dissolved in 1000mL chloroform soln jointly, prepare the mixed solution of 0.1-0.5% paclitaxel and 1-5% polylactic acid-polyglycolic acid.
In described step (4), by 30g polyvinylpyrrolidone K
30be dissolved in 1000mL pure water solution and prepare 3% polyvinylpyrrolidone K
30solution.
Advantage of the present invention and effect are the patient into easily there is stricture of ureter or restenosis after some particular procedure removing after operation ureter brackets, and a kind of ureter bracket that loads medicine is provided.This ureter bracket not only has mechanical expansion effect in implantation, and by surperficial slow release cell proliferation medicine, suppresses the hyperplasia of scar tissue, and after reaching ureter bracket and pulling out, patient is difficult for occurring the effect of stricture of ureter or restenosis.
Brief description of the drawings
Fig. 1---preparation flow schematic diagram of the present invention.
Detailed description of the invention
Technical thought of the present invention is:
Prepare a kind of polymeric medicine solution that suppresses scar tissue hyperplasia function and have slow release characteristic that has, by this solution by dip-coating czochralski method coating in the different journey section surfaces of ureter bracket, obtaining after dry can be at the novel ureter bracket of selectivity position slow releasing pharmaceutical.
Illustrate the present invention below.
Slow releasing pharmaceutical solution formula:
By 1-5g paclitaxel and 10-50g polylactic acid-polyglycolic acid (PLGA, L: G=50: 50) be jointly dissolved in 1000mL chloroform soln and prepare 0.1-0.5% paclitaxel and 1-5% polylactic acid-polyglycolic acid mixed solution.
The outer hydrophilic solution formula of slow releasing pharmaceutical:
By 30g polyvinylpyrrolidone K
30be dissolved in 1000mL pure water solution and prepare 3% polyvinylpyrrolidone K
30solution.
Medication coat ureter bracket is made explanation:
Embodiment 1:
As shown in Figure 1, under room temperature, ureter bracket 30min is cleaned in ultrasonic concussion, to under ureter bracket, 1/2 insert the mixing in chloroform soln of 0.1% paclitaxel and 1% polylactic acid-polyglycolic acid, magnetic agitation 6h, then take out ureter bracket, at the dry 12h of 37 DEG C of drying baker, then will under ureter bracket, 1/2 insert 3% polyvinylpyrrolidone K
30solution 1min takes out fast, at the dry 12h of 37 DEG C of drying baker.Support is hollow shape.
Embodiment 2:
As shown in Figure 1, under room temperature, ureter bracket 30min is cleaned in ultrasonic concussion, under room temperature, will on ureter bracket, 1/2 insert in the chloroform soln of 0.5% paclitaxel and 5% polylactic acid-polyglycolic acid (PLGA), magnetic stirrer 6h, then take out ureter bracket, at the dry 12h of 37 DEG C of drying baker, then will on ureter bracket, 1/2 insert 3% polyvinylpyrrolidone K
30solution 1min takes out fast, at the dry 12h of 37 DEG C of drying baker.
Embodiment 3:
As shown in Figure 1, under room temperature, ureter bracket 30min is cleaned in ultrasonic concussion, under room temperature, will on ureter bracket, 1/2 insert in the chloroform soln of 0.3% paclitaxel and 3% polylactic acid-polyglycolic acid (PLGA), magnetic stirrer 6h, then take out ureter bracket, at the dry 12h of 37 DEG C of drying baker, then will on ureter bracket, 1/2 insert 3% polyvinylpyrrolidone K
30solution 1min takes out fast, at the dry 12h of 37 DEG C of drying baker.
Application process explanation of the present invention:
First in art, judge that the narrow position of postoperative easy generation is positioned on ureter 1/2 or lower 1/2, choose accordingly 1/2 or lower 1/2 medication coat ureter bracket, then implanted in ureter the polyvinylpyrrolidone K on implantation process medium-height trestle surface
30chance water formation lubricating film plays and is easy to implant and avoid secondary damaging action, lubricating film fast degradation after implanting, start slowly with the 0.1-0.5% paclitaxel under lubricating film on after-poppet and 1-5% polylactic acid-polyglycolic acid, steadily discharge, sustainable 1 month of release time, average rate of release meets linear degradation rule substantially, in support is implanted rear one-month period, can work in coordination with the hyperplasia that suppresses scar tissue by the mechanical expansion effect of the effect of paclitaxel cell proliferation and ureter bracket self, thereby after reaching ureter and extracting, no longer there is the effect of stricture of ureter or restenosis, and this synergism can reduce the time that postoperative ureter bracket is implanted, avoid because preventing the narrow side effect that ureter bracket brings of implanting for a long time.
Claims (5)
1. the support of prevention stricture of ureter, is characterized in that rack surface scribbles one deck slow releasing pharmaceutical, has repasted layer of polyethylene ketopyrrolidine K on slow releasing pharmaceutical layer
30.
2. the support of prevention stricture of ureter according to claim 1, is characterized in that the Lower Half of support or the first half scribble two layers.
3. the support preparation method of prevention stricture of ureter, is characterized in that step comprises:
(1) preparation slow releasing pharmaceutical solution: paclitaxel is mixed with polylactic acid-polyglycolic acid, be dissolved in chloroform soln;
(2) by ureter bracket or Lower Half insert in slow releasing pharmaceutical solution, magnetic agitation;
(3) take out ureter bracket, dry at 37 DEG C of drying baker;
(4) by ureter bracket or Lower Half insert polyvinylpyrrolidone K
30in solution and fast, take out, dry at 37 DEG C of drying baker.
4. the support preparation method of prevention stricture of ureter according to claim 3, it is characterized in that preparing in slow releasing pharmaceutical solution, 1-5g paclitaxel and 10-50g polylactic acid-polyglycolic acid are dissolved in 1000mL chloroform soln jointly, prepare the mixed solution of 0.1-0.5% paclitaxel and 1-5% polylactic acid-polyglycolic acid.
5. the support preparation method of prevention stricture of ureter according to claim 3, is characterized in that in step (4), by 30g polyvinylpyrrolidone K
30be dissolved in 1000mL pure water solution and prepare 3% polyvinylpyrrolidone K
30solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410249792.6A CN104001222A (en) | 2014-06-04 | 2014-06-04 | Stent for preventing ureterostenosis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410249792.6A CN104001222A (en) | 2014-06-04 | 2014-06-04 | Stent for preventing ureterostenosis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104001222A true CN104001222A (en) | 2014-08-27 |
Family
ID=51362303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410249792.6A Pending CN104001222A (en) | 2014-06-04 | 2014-06-04 | Stent for preventing ureterostenosis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104001222A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111714260A (en) * | 2020-07-17 | 2020-09-29 | 上海浦瑞通医疗科技有限公司 | Support and application thereof |
| CN111839849A (en) * | 2020-07-17 | 2020-10-30 | 易浦润（上海）生物技术有限公司 | Urethral stent and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869514A (en) * | 2005-11-16 | 2010-10-27 | 学校法人东海大学 | Medicament discharges control combination thing and medicament release property medical apparatus |
| CN102908712A (en) * | 2011-08-05 | 2013-02-06 | 上海圣博艾医疗科技有限公司 | Ureteral stent and manufacturing method thereof |
-
2014
- 2014-06-04 CN CN201410249792.6A patent/CN104001222A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869514A (en) * | 2005-11-16 | 2010-10-27 | 学校法人东海大学 | Medicament discharges control combination thing and medicament release property medical apparatus |
| CN102908712A (en) * | 2011-08-05 | 2013-02-06 | 上海圣博艾医疗科技有限公司 | Ureteral stent and manufacturing method thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111714260A (en) * | 2020-07-17 | 2020-09-29 | 上海浦瑞通医疗科技有限公司 | Support and application thereof |
| CN111839849A (en) * | 2020-07-17 | 2020-10-30 | 易浦润（上海）生物技术有限公司 | Urethral stent and preparation method and application thereof |
| CN111714260B (en) * | 2020-07-17 | 2024-05-17 | 上海浦瑞通医疗科技有限公司 | Bracket and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102309368B (en) | Body lumen drug-carrying bracket and preparation method thereof | |
| US10799336B2 (en) | Medical/surgical implant | |
| CN107496051B (en) | Coated medical device and production and preparation method thereof | |
| US20070026043A1 (en) | Medical devices combined with diblock copolymer compositions | |
| US20120165937A1 (en) | Fabric with barbs coated with a water-soluble material | |
| US20160067071A1 (en) | Bioresorbable biopolymer stent | |
| AR070033A1 (en) | INJECTABLE COMPOSITIONS, THEIR PROCESSES AND USES | |
| WO2008024626A3 (en) | Bioresorbable stent with extended in vivo release of anti-restenotic agent | |
| US9433709B2 (en) | Interventional medical device and manufacturing method thereof | |
| Thors et al. | Resorbable inferior vena cava filters: trial in an in-vivo porcine model | |
| US20150004207A1 (en) | Interventional medical device and manufacturing method thereof | |
| Shekherdimian et al. | The feasibility of using an endoluminal device for intestinal lengthening | |
| CN104001222A (en) | Stent for preventing ureterostenosis and preparation method thereof | |
| CN101474455A (en) | Nano micropore structure capable of storing and releasing various kinds of medicament for medicament eluting instrument and preparation method | |
| JP6462117B2 (en) | Implantable medical device with shape memory polymer filter layer | |
| Palma et al. | Primary fixation of mini slings: a comparative biomechanical study in vivo | |
| CN102000365A (en) | Degradable bile duct bracket with stone dissolution function and preparation method thereof | |
| CN107213512B (en) | Multifunctional small-caliber artificial blood vessel with staggered-time release double slow-release coatings and preparation method thereof | |
| Attmann et al. | Advances in experimental percutaneous pulmonary valve replacement | |
| JP5601528B2 (en) | Bioabsorbable stent including contrast agent and medical device including the same | |
| CN204033851U (en) | The support of prevention stricture of ureter | |
| CN105188791B (en) | Hollow stent filled with therapeutic drug formulation | |
| WO2007092833A3 (en) | Drug delivery stent with extended in vivo drug release | |
| CN107865868B (en) | New application of amlexanox | |
| KR100916750B1 (en) | Coating agent for drug releasing stent, manufacturing method thereof and drug releasing stent coated with the coating agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140827 |